Competitive PPAR-gamma antagonists

US10093628B2 · kind B2 · utility

Assignee

• Fraunhofer-Gesellschaft zur förderung der angewandten Forschung e.V. · DE

Inventors

• Tilo Knape · Berlin, DE
• Andreas VON KNETHEN · Nidderau, DE
• Michael Parnham · Bad Soden am Taunus, DE
• Manfred Schubert-Zsilavecz · Bad Homburg vor der Höhe, DE
• Mario Wurglics · Bad Homburg vor der Höhe, DE
• Daniel Flesch · Frankfurt am Main, DE

Key dates

• Filing date: Jul 14, 2015
• Grant date: Oct 9, 2018
• Expiry date: Jul 14, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention pertains to a new compound E)-2-(5-((4-methoxy-2-(trifluoromethyl)quinolin-6-yl)methoxy)-2-((4-(trifluoromethyl) benzyl)oxy)-benzylidene) hexanoic acid (MTTB), and its derivatives. The compounds of the invention are useful as selective peroxisome proliferator-activated receptor gamma (PPARγ) antagonists and are indicated for the use in the treatment of immune related diseases such as systemic inflammation, sepsis and septic shock.